The FDA is scheduled to announce its decision on Mallinckrodt Public Limited Co.’s (MNK) supplemental New Drug Application for Amitiza in children 6 to 17 years of age with pediatric functional constipation on April 28, 2018.Amitiza came under Mallinckrodt’s fold following the acquisition of Sucampo Pharmaceuticals last December. The drug is already approved for the treatment of chronic idiopathic constipation and opioid-induced constipation in adults, and irritable bowel syndrome with constipation in adult women.The global sales of Amitiza in 2016 were $456 million.MNK closed Tuesday’s (Mar.27) trading at $13.88, down 1.21%.